RT Journal Article
SR Electronic
T1 Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.06.28.449914
DO 10.1101/2021.06.28.449914
A1 Angela Choi
A1 Matthew Koch
A1 Kai Wu
A1 Groves Dixon
A1 Judy Oestreicher
A1 Holly Legault
A1 Guillaume B.E. Stewart□Jones
A1 Tonya Colpitts
A1 Rolando Pajon
A1 Hamilton Bennett
A1 Andrea Carfi
A1 Darin K. Edwards
YR 2021
UL http://biorxiv.org/content/early/2021/06/28/2021.06.28.449914.abstract
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated as D614G). Results showed minimal effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), B.1.617.2 (Delta), and P.1 (Gamma) showed decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273–elicited serum neutralization.Competing Interest StatementA.C., M.K., K.W., G.D, J.O., H.L., G.S.-J., T.C., R.P. H.B., A.C. and D.K.E. are employed by Moderna Inc. and hold equities from the company.